Insider Tug‑of‑War at Immunome: CEO Buys Big, Scientific Officer Sells Big—What It Means for Investors

Insider Moves at Immunome Inc.: What the Latest Sell Signals About the Company’s Future

On March 30, 2026, Chief Scientific Officer Higgins Jack sold 6,291 shares of Immunome’s common stock at the market close. Although the transaction price was effectively zero—likely a “sell‑to‑cover” of a previously acquired employee‑stock‑option right—the move is noteworthy against the backdrop of a sharp uptick in company‑wide insider buying, most notably President and CEO Clay Siegall’s purchase of 25,450 shares at $19.67 a share the day before. For investors, the juxtaposition of significant buying by top leadership and a sizeable sale by a key technical officer raises questions about internal confidence and liquidity needs.

Implications for Investors

The stock has traded at a close of $21.87, up 11% over the week, with a 52‑week high of $27.65 and a low of $5.15. Despite a negative price‑earnings ratio of –7.97—indicative of current losses—Immunome’s market cap of $2.18 billion and a strong 259% year‑to‑date gain suggest the market is pricing in substantial upside. Higgins Jack’s sell may reflect a personal liquidity event or a strategic rebalancing of his portfolio, rather than a bearish signal on the business. However, the fact that the sale coincided with a period of intense social‑media buzz (44% higher than normal) could amplify market perception, potentially contributing to short‑term volatility.

What the Pattern of Jack’s Insider Activity Shows

Jack’s trading history over the past 18 months paints a picture of an insider who alternates between exercising and selling employee‑stock‑option rights while maintaining a substantial equity stake. In December 2025 he sold 39,729 shares and bought 1,000, then again sold 38,729 shares and bought another 1,000—an almost perfect “sell‑buy‑sell‑buy” sequence that suggests disciplined, possibly tax‑aware trading. Earlier this year, he exercised a 196,000‑share option in July 2025, then sold 22,000 shares in September, and bought 22,000 shares at $1.35 each—an aggressive cycle of option exercise and subsequent market purchase.

The recurring pattern of option exercise followed by a sell of a comparable block indicates that Jack is likely using stock‑based compensation to fund personal investments or to lock in gains as the stock price rises. His post‑transaction holdings consistently remain above 30,000 shares, underscoring a long‑term commitment to the company’s equity. This contrasts with the CEO’s large purchase, which signals confidence in imminent positive developments—perhaps new product pipelines or regulatory milestones that could lift the share price further.

Strategic Outlook for Immunome

With a robust pipeline of therapeutic antibodies and a growing presence in the biotech space, Immunome’s fundamentals appear poised for a turnaround. The recent CEO buy, combined with Jack’s continued stake, suggests that insiders remain optimistic, even if personal liquidity needs trigger periodic sales. For investors, the key takeaways are: (1) monitor the stock’s price action around insider transactions, as they can create short‑term volatility; (2) watch for upcoming earnings or FDA approvals that could justify the negative P/E ratio and support a higher valuation; and (3) consider the long‑term insider commitment as a positive signal of alignment between management and shareholders.

In sum, Higgins Jack’s sell is a routine liquidity move rather than a harbinger of decline. Coupled with the CEO’s significant buying, the insider activity at Immunome Inc. points toward a company that is still in a growth phase, with insiders confident that the next wave of scientific breakthroughs will drive shareholder value upward.